Hosu-53

N/A

Report date: 2026/02/04 15:04:01
NME

Base Information

Drug NameHosu-53
Drug Alias NameHosu-53HOSU-53JBZ-001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydroorotate dehydrogenase inhibitors
TargetsDihydroorotate dehydrogenase
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOhio State University Comprehensive Cancer CenterJabez Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesJabez Bioscience IncJabez Biosciences IncOhio State University Comprehensive Cancer Center
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A